George Hill

how would you guys characterize your fee-for-service pricing power as it relates to distribution agreements

should we expect to see manufacturer branded price decreases I'm sorry, not increases, decreases impact either the revenue line or the operating income line as we think about calendar 2026

it seems like you're actually assuming a deceleration in the balance of the year. And I guess there's the M&A component of that. But I guess I'd like you to talk about the sustainability of the beat

Are there any marks on the liability that will run through the income statement in future periods? Kind of like what's the offset for the NCI going away? And are you able to quantify the value of t...

I was just wondering if maybe you could attribute the margin expansion rank-order

I was wondering if you guys would either just maybe attribute kind of vaccine versus it sounds like GLP-1s weren't much versus generics

I was just hoping you might update us on your 340B exposure given where you guys are with Carepath now and Shields

can you say whether that was a like, was that was the carrying of that business a net drag on earnings in the quarter

are there any other considerations on the stop loss margin recovery besides price, as it relates looking at the '26 or '27 that we should be meaningfully thinking about

when those issues get addressed, they tend to come out of the rate from a state perspective

does that include the Florida retro and what's changed in New York

I wanna make sure that you meant pharma pricing pressure versus pharmacy pricing pressure

I thought that you had said there could be some upside in Q1 if the FTR hits later in the year and get back towards the normal guidance range

is there any change you would give us what portion of the AOI in the U.S. segment now comes from physician administered or I'll call them Part B businesses

could you unpack a little bit of the revenue guidance change in the US business? It's about $5.7 billion

has the business inflected to a point the margin expansion, as indicated by the guidance this year, operating earnings growing faster than revenue growth is sustainable on an ongoing basis

I'm wondering if you could comment a little bit on the competitive environment in specialty distribution, especially in the Part B space

if you could kind of quickly walk through the RCA impact on gross margin expansion in the quarter, I think that would be helpful

could you rank order the value drivers that allow, whether it's Cencora or RCA or OneOncology, to add value to its physician partners

how are you guys thinking about how you support those practices given the headwinds that could come from IRA

Like how focused are you guys on retaining share in that space? How has the margin profile progressed in that space

I was just wondering if you might provide any color on kind of the directional pieces inside of MA, Medicaid, Commercial

how far are we away from like the long-term guidance of down 5% not being the case anymore

Maybe could you break out if there's any changes in the vaccine outlook, talk about the impact of reimbursement stabilization

we saw a pretty big step-up in base claims payable, both sequentially and year-over-year. I was wondering 2 things

can you just contextualize a little bit more what does the ending baseline mean

is there a way to put a bottom goalpost around Medicaid expectations for '26? You said you expect it to be greater than -- or call it, down about 125 basis points

can you kind of quantify the expectation there. And are there any other onetime items or things that you would call out in the guide as it relates to the back of the year

could you talk about the V28, your expected impact from the V28 risk model change this year kind of as it relates to last year

do you guys have an expectation for what happens to the enhanced subsidies as part of the upcoming political cycle

could you provide a little bit more color on what's driving the bounce back on the members that are returning to Humana intra year

I wanted to follow-up on the visibility to cost trend. Celeste, said you had data through the April

are you seeing anything that's kinda changed your margin outlook or expectation for Part D in 2025?

I would just love if you could opine what you've seen from pricing actions from branded drug manufacturers

is there any operating impact to this as it relates to the financials

Should the implication be that, I guess, either PTS or medical might come in at the low end of the guidance ranges

the recognition of the cost savings in the Medical segment for the back half of this fiscal year seems to be nonlinear

could you quantify the PYD or the impact of the PYD in the quarter?

can you quantify the step-up in investments that were incurred in Q3? And how much of those should we think of as run rate investments